Cannabinoid treatment for autism: a proof-of-concept randomized trial

BACKGROUND: Endocannabinoid dysfunction in animal models of autism spectrum disorder (ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this placebo-controlled double-blind comparison of two oral cannabinoid solutions in 150 participants (age 5–21 years) with ASD. ME...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Mol Autism
Hoofdauteurs: Aran, Adi, Harel, Moria, Cassuto, Hanoch, Polyansky, Lola, Schnapp, Aviad, Wattad, Nadia, Shmueli, Dorit, Golan, Daphna, Castellanos, F. Xavier
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BioMed Central 2021
Onderwerpen:
Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7860205/
https://ncbi.nlm.nih.gov/pubmed/33536055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13229-021-00420-2
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items